Date: 2011-10-30
Type of information: R&D agreement
Compound: therapeutic monoclonal antibodies for the treatment of cancer
Company: Antitope (UK) Kolltan Pharmaceuticals (USA)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease: cancer
Details: Antitope has announced a research agreement with Kolltan Pharmaceuticals for the generation of therapeutic monoclonal antibodies for the treatment of cancer. Under the agreement, Antitope will apply its proprietary Composite Human Antibody™ technology for the generation of humanized antibodies.
Financial terms:
Latest news:
